Table 2.

Predictors of Discontinuing Active Surveillance

	# patients (%)	Hazard Ratio (95% CI)	p-value
PSA (log) (per ng/ml)	---	1.02 (0.90–1.15)	0.7
Age (per year)	---	0.99 (0.95–1.03)	0.8
Clinical stage
T1a/b	20 (7%)	0.91 (0.32–2.57)	0.9
T1c	198 (76%)	REF
T2a	39 (15%)	0.87 (0.36–2.07)
Prostate volume (ultrasound or MRI)
<30 cc	52 (24%)	REF	0.6
30–50 cc	74 (34%)	0.59 (0.23–1.53)
>50 cc	90 (42%)	0.75 (0.32–1.71)
Repeat biopsy with cancer
No	159 (61%)	REF
Yes	103 (39%)	2.23 (1.23–4.06)	0.007
Total cores from both biopsies (per core)	---	1.02 (0.99–1.06)	0.25
Total positive cores from both biopsies
1–2	178	REF	0.002
3–4	42	1.4 (1.11–1.94)
5–6	8	6.3 (1.72–15.36)